{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:27:39Z","timestamp":1740126459555,"version":"3.37.3"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100003185","name":"National Psoriasis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003185","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CorEvitas LLC"},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals, Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Sanofi, Sun Pharmaceutical Industries Ltd and UCB S.A."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Early identification, diagnosis and symptom control of psoriatic arthritis (PsA) in patients with psoriasis remain unmet medical needs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To compare the impact of disease and other characteristics between patients with psoriasis who screened positive for PsA using the Psoriasis Epidemiology Screening Tool (PEST) (screen-positive group) and patients who (i) have PsA (PsA group) or (ii) screened negative for PsA (screen-negative group). Also, to determine the proportion of patients at a patient-acceptable symptom state (PASS) in the screen-positive and PsA groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This was a cross-sectional analysis of the CorEvitas Psoriasis Registry. We included a convenience sample of patients with psoriasis from the screen-positive and PsA groups who completed the Psoriatic Arthritis Impact of Disease-12 (PsAID12), and a comparator screen-negative group who did not complete the PsAID12. We report descriptive summaries of demographics, comorbidities, psoriasis characteristics, patient-reported outcome measures and the proportion of patients at PASS (i.e. PsAID12 \u2264 4).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The screen-positive, PsA and screen-negative groups included 369,\u00a070 and 4724 patients, respectively. The screen-positive and PsA groups had a similar impact of disease, demographics, comorbidities and psoriasis characteristics (d &amp;lt; 0.337). Mean PsAID12 scores were 3.1 (SD 2.3) and 3.7 (SD 2.6) in the screen-positive and PsA groups, respectively. Compared with patients who screened negative for PsA, patients who screened positive exhibited higher rates of selected known predictors of PsA such as older age, longer psoriasis duration, nail disease and inverse psoriasis. The proportion of patients at PASS was 56% and 67% for the PsA and screen-positive groups, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The similar profiles between screen-positive and PsA groups, in comparison with the screen-negative group, support observations of possible underdiagnosis of PsA and the increased impact of disease, especially musculoskeletal disease, among patients who screen positive for PsA. The high percentage of patients not at an acceptable symptom state in the PsA and screen-positive groups highlights the need to optimize care in PsA.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ced\/llae095","type":"journal-article","created":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T13:27:49Z","timestamp":1715434069000},"page":"1016-1023","source":"Crossref","is-referenced-by-count":0,"title":["Impact of disease, musculoskeletal symptoms and disease control in the CorEvitas Psoriasis Registry"],"prefix":"10.1093","volume":"49","author":[{"given":"Carly","family":"Grant","sequence":"first","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lourdes M","family":"Perez-Chada","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan W","family":"Harrison","sequence":"additional","affiliation":[{"name":"CorEvitas LLC , Waltham, MA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert R","family":"McLean","sequence":"additional","affiliation":[{"name":"CorEvitas LLC , Waltham, MA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Blessing","family":"Dube","sequence":"additional","affiliation":[{"name":"CorEvitas LLC , Waltham, MA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaux M","family":"Crabtree","sequence":"additional","affiliation":[{"name":"CorEvitas LLC , Waltham, MA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice B","family":"Gottlieb","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai , New York, NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph F","family":"Merola","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA , USA"},{"name":"Division of Rheumatology, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,3,5]]},"reference":[{"key":"2024082301134495000_llae095-B1","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1001\/jamadermatol.2021.2007","article-title":"Psoriasis prevalence in adults in the United States","volume":"157","author":"Armstrong","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2024082301134495000_llae095-B2","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","article-title":"Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/North American dermatology clinics","volume":"69","author":"Mease","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"2024082301134495000_llae095-B3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40744-016-0029-z","article-title":"Psoriatic arthritis and burden of disease: patient perspectives from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey","volume":"3","author":"Kavanaugh","year":"2016","journal-title":"Rheumatol Ther"},{"issue":"Suppl. 2","key":"2024082301134495000_llae095-B4","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2024082301134495000_llae095-B5","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/09546630600823369","article-title":"Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists\u2019 offices","volume":"17","author":"Gottlieb","year":"2006","journal-title":"J Dermatolog Treat"},{"key":"2024082301134495000_llae095-B6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s12016-017-8630-7","article-title":"Clinical features of psoriatic arthritis: a comprehensive review of unmet clinical needs","volume":"55","author":"McArdle","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"2024082301134495000_llae095-B7","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10067-017-3908-y","article-title":"Current concepts and unmet needs in psoriatic arthritis","volume":"37","author":"Mahmood","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2024082301134495000_llae095-B8","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2021.101693","article-title":"Unmet needs in psoriatic arthritis","volume":"35","author":"Ng","year":"2021","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2024082301134495000_llae095-B9","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/jdv.15443","article-title":"Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross-sectional analysis from the US-based Corrona Psoriasis Registry","volume":"33","author":"Mease","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024082301134495000_llae095-B10","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jaad.2015.05.001","article-title":"Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis","volume":"73","author":"Villani","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2024082301134495000_llae095-B11","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jamadermatol.2013.5264","article-title":"Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation Surveys, 2003-2011","volume":"149","author":"Armstrong","year":"2013","journal-title":"JAMA Dermatol"},{"key":"2024082301134495000_llae095-B12","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s40744-022-00443-y","article-title":"Residual disease associated with suboptimal treatment response in patients with psoriatic arthritis: a systematic review of real-world evidence","volume":"9","author":"Coates","year":"2022","journal-title":"Rheumatol Ther"},{"key":"2024082301134495000_llae095-B13","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jaad.2019.05.075","article-title":"Measuring psoriatic arthritis symptoms: a core domain in psoriasis clinical trials","volume":"82","author":"Perez-Chada","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2024082301134495000_llae095-B14","first-page":"10","article-title":"Report of the Skin Research Working Groups from the GRAPPA 2020 annual meeting","volume":"97","author":"Perez-Chada","year":"2021","journal-title":"J Rheumatol Suppl"},{"key":"2024082301134495000_llae095-B15","first-page":"469","article-title":"Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire","volume":"27","author":"Ibrahim","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"2024082301134495000_llae095-B16","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/annrheumdis-2014-205207","article-title":"A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative","volume":"73","author":"Gossec","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2024082301134495000_llae095-B17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jaad.2017.10.012","article-title":"Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: results from the Corrona Psoriasis Registry","volume":"78","author":"Strober","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2024082301134495000_llae095-B18","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40257-019-00496-w","article-title":"Investigator and patient global assessment measures for psoriasis clinical trials: a systematic review on measurement properties from the International Dermatology Outcome Measures (IDEOM) initiative","volume":"21","author":"Perez-Chada","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"2024082301134495000_llae095-B19","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1159\/000499925","article-title":"Exploration of the product of the 5-point Investigator's Global Assessment and Body Surface Area (IGA \u00d7 BSA) as a practical minimal disease activity goal in patients with moderate-to-severe psoriasis","volume":"235","author":"Gottlieb","year":"2019","journal-title":"Dermatology"},{"key":"2024082301134495000_llae095-B20","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jaad.2013.07.040","article-title":"Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort","volume":"69","author":"Walsh","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"2024082301134495000_llae095-B21","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI) \u2013 a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"2024082301134495000_llae095-B22","doi-asserted-by":"crossref","first-page":"R177","DOI":"10.1186\/ar3141","article-title":"Validity of the work productivity and activity impairment questionnaire \u2013 general health version in patients with rheumatoid arthritis","volume":"12","author":"Zhang","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"2024082301134495000_llae095-B23","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann Med"},{"key":"2024082301134495000_llae095-B24","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An Introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"volume-title":"Statistical Power Analysis for the Behavioral Sciences","year":"1988","author":"Cohen","key":"2024082301134495000_llae095-B25"},{"key":"2024082301134495000_llae095-B26","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/00031305.1986.10475403","article-title":"Standard distance in univariate and multivariate analysis","volume":"40","author":"Flury","year":"1986","journal-title":"Am Stat"},{"key":"2024082301134495000_llae095-B27","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"2024082301134495000_llae095-B28","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13075-020-02168-1","article-title":"Disease features associated with a low disease impact in patients with psoriatic arthritis: results of a cross-sectional multicenter study","volume":"22","author":"Queiro","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2024082301134495000_llae095-B29","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/acr.23176","article-title":"Associations between five important domains of health and the patient acceptable symptom state in rheumatoid arthritis and psoriatic arthritis: a cross-sectional study of 977 patients","volume":"69","author":"Puyraimond-Zemmour","year":"2017","journal-title":"Arthritis Care Res (Hoboken"},{"issue":"Suppl. 10","key":"2024082301134495000_llae095-B30","article-title":"The impact of skin involvement and depression on patient acceptable symptom state in patients with psoriatic arthritis and psoriasis: results from a multinational survey","volume":"73","author":"Ogdie-Beatty","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2024082301134495000_llae095-B31","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001170","article-title":"Assessment of the patient acceptable symptom state (PASS) in psoriatic arthritis: association with disease activity and quality of life indices","volume":"6","author":"Lubrano","year":"2020","journal-title":"RMD Open"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae095\/57525923\/llae095.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/9\/1016\/58892985\/llae095.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/9\/1016\/58892985\/llae095.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T04:21:08Z","timestamp":1724386868000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/49\/9\/1016\/7669025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,5]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,3,5]]},"published-print":{"date-parts":[[2024,8,22]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae095","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"type":"print","value":"0307-6938"},{"type":"electronic","value":"1365-2230"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,3,5]]}}}